Table of Contents
Chromatography Research International
Volume 2014, Article ID 736761, 8 pages
http://dx.doi.org/10.1155/2014/736761
Research Article

Development and Validation of a Novel RP-HPLC Method for Estimation of Losartan Potassium in Dissolution Samples of Immediate and Sustained Release Tablets

1Research Scholar, Ultra College of Pharmacy, 4/235 College Road, Thasildar Nagar, Madurai, Tamil Nadu 625020, India
2Department of Pharmaceutical Chemistry, Ultra College of Pharmacy, 4/235, College Road, Thasildar Nagar, Madurai, Tamil Nadu 625020, India

Received 26 October 2013; Accepted 11 March 2014; Published 9 April 2014

Academic Editor: Irene Panderi

Copyright © 2014 Harshal A. Pawar and K. G. Lalitha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Azarmi, W. Roa, and R. Löbenberg, “Current perspectives in dissolution testing of conventional and novel dosage forms,” International Journal of Pharmaceutics, vol. 328, no. 1, pp. 12–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. The United States Pharmacopoeia Drug Information, vol. 1, The United States Pharmacopoeia Convention, Rockville, Md, USA, 18th edition, 1998.
  3. S. B. Wankhede, K. C. Raka, S. B. Wadkar, and S. S. Chitlange, “Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets,” Indian Journal of Pharmaceutical Sciences, vol. 72, no. 1, pp. 136–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Pitt, R. Segal, F. A. Martinez et al., “Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE),” Lancet, vol. 349, no. 9054, pp. 747–752, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. K. E. McCarthy, Q. Wang, E. W. Tsai, R. E. Gilbert, D. P. Ip, and M. A. Brooks, “Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 17, no. 4-5, pp. 671–677, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. R. Sathe and S. B. Bari, “Simultaneous analysis of losartan potassium, atenolol, and hydrochlorothiazide in bulk and in tablets by high-performance thin-layer chromatography with UV absorption densitometry,” Acta Chromatographica, no. 19, pp. 270–278, 2007. View at Google Scholar · View at Scopus
  7. M. G. Quaglia, E. Donati, G. Carlucci, P. Mazzeo, and S. Fanali, “Determination of losartan and hydrochlorothiazide in tablets by CE and CEC,” Journal of Pharmaceutical and Biomedical Analysis, vol. 29, no. 6, pp. 981–987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. O. C. Lastra, I. G. Lemus, H. J. Sánchez, and R. F. Pérez, “Development and validation of an UVderivative spectrophotometric determination of Losartan potassium in tablets,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 2, pp. 175–180, 2003. View at Google Scholar
  9. R. M. Maggio, P. M. Castellano, and T. S. Kaufman, “A multivariate approach for the simultaneous determination of losartan potassium and hydrochlorothiazide in a combined pharmaceutical tablet formulation,” Analytical and Bioanalytical Chemistry, vol. 391, no. 8, pp. 2949–2955, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. H. Prabhakar and R. Giridhar, “A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form,” Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 6, pp. 861–866, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Hertzog, J. F. McCafferty, X. Fang, R. J. Tyrrell, and R. A. Reed, “Development and validation of a stability-indicating HPLC method for the simultaneous determination of Losartan potassium, hydrochlorothiazide, and their degradation products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 30, no. 3, pp. 747–760, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Erk, “Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 4, pp. 603–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Carlucci, G. Palumbo, P. Mazzeo, and M. G. Quaglia, “Simultaneous determination of losartan and hydrochlorothiazide in tablets by high-performance liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 1, pp. 185–189, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Williams, M. S. Alasandro, V. L. Fasone, R. J. Boucher, and J. F. Edwards, “Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets,” Journal of Pharmaceutical and Biomedical Analysis, vol. 14, no. 11, pp. 1539–1546, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Özkan, C. Akay, Ş. Cevheroglu, and Z. Şentürk, “Rapid and accurate simultaneous determination of fosinopril sodium and hydrochlorothiazide in tablets by HPLC,” Journal of Liquid Chromatography and Related Technologies, vol. 24, no. 7, pp. 983–991, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. ICH, “Q2 (R1) validation of analytical procedure, test and methodology,” in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 2005.
  17. ICH, Q2A. Validation of Analytical Procedures, Consensus Guidelines, ICH Harmonized Tripartite Guidelines, 1994.
  18. ICH, Q2B. Validation of Analytical Procedures: Methodology, Consensus Guidelines, ICH Harmonized Tripartite Guidelines, 1996.
  19. United States Pharmacopoeia, United States Pharmacopoeial Convention, Rockville, Md, USA, 31st edition, 2007.
  20. USP General Chapter on Dissolution, United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention, Rockville, Md, USA, 2006.
  21. FDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, US Department of Health and Human Services, Centre for Drug Evaluation and Research (CEDER), Food and Drug Administration, Rockville, Md, USA, 1997.
  22. ICH, “(Q2R1) Guideline on validation of analytical procedures: text and methodology,” in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 2007.
  23. USP General Chapter on the Dissolution Procedure: Development and Validation, United States Pharmacopeia and National Formulary, United States Pharmacopoeial Convention, Rockville, Md, USA, 2006.
  24. “US Pharmacopeial Forum,” Pharmacopoeial Previews, vol. 30, pp. 351–363, 2004.
  25. US Pharmacopoeia NF-25, The Dissolution Procedure: Development and Validation, US Pharmacopoeial Convention, Rockville, Md, USA, 32nd edition, 2009.
  26. C. K. Brown, H. P. Chokshi, B. Nickerson, R. A. Reed, B. R. Rohrs, and P. A. Shah, “Acceptable analytical practices for dissolution testing of poorly soluble compounds,” Pharmaceutical Technology, vol. 28, no. 12, pp. 56–65, 2004. View at Google Scholar · View at Scopus
  27. G. Freitag, “Guidelines on dissolution profile comparison,” Drug Information Journal, vol. 35, no. 3, pp. 865–874, 2001. View at Google Scholar · View at Scopus
  28. K. E. McCarthy, Q. Wang, E. W. Tsai, R. E. Gilbert, D. P. Ip, and M. A. Brooks, “Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 17, no. 4-5, pp. 671–677, 1998. View at Publisher · View at Google Scholar · View at Scopus